In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 5, 2003, Pages 1203-1211

  Dawis, Maria Agnes ^a   Isenberg, Henry D ^a,b   France, Kenneth A ^a   Jenkins, Stephen G ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Fluoroquinolones; Gatifloxacin; Susceptibility testing; Synergy

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; GATIFLOXACIN; GENTAMICIN; MEROPENEM; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIA; CEPHALOSPORINS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; FLUOROQUINOLONES; GENTAMICINS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PIPERACILLIN; THIENAMYCINS;

EID: 0038101668     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg238     Document Type: Article

References (26)

1. Eliopoulos, G. M. & Eliopoulos, C. T. (1988). Antibiotic combinations: should they be tested? Clinical Microbiology Reviews 1, 139-56.
2. Takei, M., Fukuda, H., Yasue, T., Hosaka, M. & Oomori, Y. (1998). Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrobial Agents and Chemotherapy 42, 2678-81.
3. Zhao, X., Xu, C., Domagala, J. & Drlica, K. (1997). DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proceedings of the National Academy of Sciences, USA 94, 13991-6.
4. Zhao, X., Wang, J. Y., Xu, C., Dong, Y., Zhou, J., Domagala, J. et al. (1998). Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrobial Agents and Chemotherapy 42, 956-8.
5. Lu, T., Zhao, X. & Drlica, K. (1999). Gatifloxacin activity against quinolone resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrobial Agents and Chemotherapy 43, 2969-74.
6. Marutani, K., Matsumoto, M., Otabe, Y., Nagamuta, M., Tanaka, K., Miyoshi, A. et al. (1993). Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrobial Agents and Chemotherapy 37, 2217-23.
7. Fung-Tomc, J., Minassian, B., Kolek, B., Washo, T., Huczko, E. & Bonner, D. (2000). In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Journal of Antimicrobial Chemotherapy 45, 437-46.
8. Blondeau, J. M., Laskowski, R., Bjarnason, J. & Stewart, C. (2000). Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. International Journal of Antimicrobial Agents 14, 45-50.
9. Huczko, E., Conetta, B., Bonner, D., Valera, L., Stickle, T., Macko, A. et al. (2000). Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998. International Journal of Antimicrobial Agents 16, 401-5.
10. Gales, A. C., Jones, R. N., Forward, K. R., Linares, J., Sader, H. S. & Verhoef, J. (2001). Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clinical Infectious Diseases 15, Suppl. 32 no. 2, S104-13.
11. Mangram, A. & Jarvis, W. R. (1996). Nosocomial Burkholderia cepacia outbreaks and pseudo-outbreaks. Infection Control and Hospital Epidemiology 17, 718-20.
12. National Nosocomial Infection Surveillance (NNIS) System. (2000). National Nosocomial Infection Surveillance (NNIS) System report, data summary from January 1992-April 2000. American Journal of Infection Control 27, 520-32.
13. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA.
14. Eliopoulos, G. M. & Moellering, R. C., Jr (1991). Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 3rd edn (Lorian, V., Ed.), pp. 432-49. Williams and Wilkins Co., Baltimore, MD, USA.
15. National Committee for Clinical Laboratory Standards. (2000). MIC Testing Supplemental Tables: NCCLS publication no. M100-S10 (M7). NCCLS, Villanova, PA, USA.
16. Biedenbach, D. J., Croco, M. A., Barrett, T. J. & Jones, R. N. (1999). Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E Test methods. European Journal of Clinical Microbiology and Infectious Diseases 18, 428-31.
17. Weiss, K., Restieri, C., De Carolis, E., Laverdiere, M. & Guay, H. (2000). Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. Journal of Antimicrobial Chemotherapy 45, 363-5.
18. Jones, R. N., Beach, M. L. & Pfaller, M. A. (2001). Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagnostic Microbiology and Infectious Disease 41, 161-3.
19. Paterson, D. L., Mulazimoglu, L., Casellas, J. M., Ko, W. C., Goossens, H., Von Gottberg, A. et al. (2000). Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clinical Infectious Diseases 30, 473-8.
20. Isenberg, H. D., Alperstein, P. & France, K. (1999). In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagnostic Microbiology and Infectious Disease 33, 81-6.
21. Jenkins, S. G. & Lewis, J. W. (1995). Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens. Infection 23, 154-61.
22. Neu, H. (1989). Synergy of fluoroquinolones with other antimicrobial agents. Reviews of Infectious Diseases 11, Suppl. 5, S1025-35.
23. Poulos, C. D., Matsumura, S. O., Willey, B. M., Low, D. E. & McGeer, A. (1995). In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrobial Agents and Chemotherapy 39, 2220-3.
24. Gradelski, E., Kolek, B., Bonner, D. P., Valera, L., Minassian, B. & Fung-Tomc, J. (2001). Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. International Journal of Antimicrobial Agents 17, 103-7.
25. Gradelski, E., Valera, L., Bonner, D. & Fung-Tomc, J. (2001). Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Antimicrobial Agents and Chemotherapy 45, 3220-2.
26. Fish, D. N., Choi, M. K. & Jung R. (2002). Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. Journal of Antimicrobial Chemotherapy 50, 1045-9.